Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 Read more about Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
PHAXIAM Reports Third-Quarter 2024 Financial Information Read more about PHAXIAM Reports Third-Quarter 2024 Financial Information
Communication operations of Members of the Board Read more about Communication operations of Members of the Board
Financial information for the period ended 30 September 2024 Read more about Financial information for the period ended 30 September 2024
Mersen: 2025 provisional financial calendar Read more about Mersen: 2025 provisional financial calendar
Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions Read more about Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions
Mandatory notification of trade by primary insider Read more about Mandatory notification of trade by primary insider
Å Energi: Successful Issuance of new Green NOK Bond Issue and Tap issues Read more about Å Energi: Successful Issuance of new Green NOK Bond Issue and Tap issues
Norlandia Health & Care Group AS-Larsen Submitted by master_of_puppets on Wed 13/11/2024 - 17:11 Read more about Norlandia Health & Care Group AS-Larsen